GPRC5A and metastatic neoplasm: In both groups, high GPRC5A was significantly associated with worse overall survival (OS) and with shorter progression‐free survival (PFS) in the metastatic tumors (Fig 9C and D, Appendix Table S4; OS: P = 0.044 and 0.012, PFS: P = 0.009).